During the past 7 years, BioSquare has become the most attended biotech partnering conference taking place in the first half of the year.
BioSquare strengths rely mainly on its very high quality of participants. Indeed, top business executives from biotech, Business developers from large corporations as well as high ranking financiers gather at BioSquare to make business.
The three-day event features a full program including panels and workshops led by corporate executives and biotech experts.
BioSquare also features a company presentation track including not only the up and coming biotech companies but also the largest Life Sciences companies presenting their in/out licensing strategies.
BioSquare offers a sophisticated internet partnering software system, designed for the industry, allowing conference participants to quickly identify potential partners, organize and schedule meetings beforehand to optimize the opportunity to create sustainable, long term business partnerships.
European leader in fresh human and animal hepatocytes, we provide human skin derived products for passage studies, human renal proximal tubule cells, dendritic cells, plasma, whole blood, hepatic and extra-hepatic microsomes, liver and lung slices. We are the exclusive producer of the human hepatic cells, HepaRG, fully equipped with CYPs and drug transporters. We will be pleased to give you more details on our booth.
C.RIS Pharma is a French biotech company specialized in in vitro and in vivo preclinical development of new drugs especially in the Cancer area, Neurodegenerative, Genetic and Metabolic diseases, but also in Agrofood and Cosmetic area.
CHELATEC is a Contract Research Organisation dedicated to Radiolabelling and Preclinical Studies for the development of innovative labelled products. Our skills in Nuclear Medicine and Radiopharmacy allow the integration into the selection process of Chemistry, Radiochemistry, Biochemistry, Biology, in vivo experimentation and Imaging. Today and since more than 7 years, more than 20 International Pharmaceuticals and Biotechs companies are our partners.
The VIASKIN® technology is a unique delivery system which uses electrostatic forces to retain active compounds on a carrier and delivers them to the epidermis of the skin without breaking the blood-skin barrier. Allergy diagnosis and specific immunotherapy – combining technology and expertise in the field of paediatric and adult allergy, DBV intends to become a leader in the non-invasive diagnosis of allergy through its product range DIALLERTEST®. In early clinical trials, positive desensitisation of severe food allergy patients has been achieved with VIASKIN® treatment with no systemic shock (milk and peanuts). Epicutaneous vaccination – A promising delivery method which is the subject of ongoing research and is perfectly suited to VIASKIN® technology. Pre-clinical trials have shown encouraging results for different vaccine models.
ERYtech Pharma is a biotech company focused on the development of new medicinal products forms: therapeutic molecules or enzymes encapsulated into red blood cells. It offers innovative therapeutic solutions by significantly increasing the therapeutic index of the encapsulated molecules and reducing their side-effects. Primarely focused on cancer therapies, ERYtech Pharma aims at developing products which answer the need for offering a better comfort to patients, returning side-effects and improving efficacy.
Thanks to its bioinformatic platform, GENEPEP R&D provides libraries of new endogenous peptides from vastly various species (human, mammals, insects, amphibians marine organisms…) or tissues (skin, venom glands, tumoral prostate, brain…) ; GENEPEP can also give access to its bioinformatic platform for cDNA analysis (identification of secreted peptides encoded by cDNA) or create new custom softwares. GENEPEP SERVICES is specialized in custom peptide synthesis, peptide/protein sequencing, antibodies, mass analysis.
Founded in 1999, Genfit is a public biopharmaceutical company headquartered in Lille, France with its US subsidiary in Cambridge, Massachusetts. As a cardiometabolic company, Genfit has focused its efforts in prevention and treatment of common risk factors associated with cardiovascular and metabolic disorders such as atherosclerosis, dyslipidemia, hypertension, diabetes, and obesity. In addition, Genfit has a special interest in selected indications such as Alzheimer’s and Parkinson’s disease within the neurodegenerative field as well as other indications in anti-inflammatory area. Genfit’s strategy of single-drug therapy, the “multimodal” approach, is based on development of novel drugs with a single active ingredient to address multiple risk factors in a related disorder and hence eliminating the potential drug-drug interaction side effects associated with multiple-drug therapy.
Idealp-Pharma is a well known, self -funded, privately-held company wich provides a flexible working approach from stand-alone services in medicinal chemistry or cheminformatics to integrated projects including capabilities in chemistry, computational chemistry and biology. Idealp-Pharma is the ideal partner for providing outsourced research to Pharma and Biotech clients and thus improving their productivity in Drug Discovery.
Iris Pharma, a world-class service company for global drug and device development in ophthalmology, provides: bioanalytical testing service; pre-clinical formulation; pre-clinical studies (proof of concept, pilot, GLP) and animal models; Phase I to IV clinical trials in Europe and North America; and strategic consulting. Since 1989, it has been offering ophthalmologic drug and device development services to more than 100 pharmaceutical and biotechnology companies worldwide. Expertise : angiogenesis, neurodegeneration, glaucoma, inflammation, allergy, infection, dry eye…
Mapreg is a biotechnology company specialized in the discovery and development of new drugs for the treatment of diseases of the central nervous system, first acute pathologies. These drugs, neurosteroid derivatives, exploit a new mechanism of action that has been discovered in the laboratory of Etienne-Emile Baulieu, Mapreg’s president. The first clinic candidate, MAP 4343, has recently received by EMEA an orphan designation for the treatment of Spinal Cord Injury.
We are experts in strategic recruitment from mid-management to top executives in the Pharma, Biotech and Cleantech industries. We work as well with Private Equity firms in those fields. Our goal: to accompany your innovations as your long term recruiting Partner. We are proud to have 100% quality – Zero defect processes and a very probe approach. Our code of Ethics and values of tolerance are shared with our Clients and Candidates. This is why we have a track record of 21 years of expertise and are amongst Europe's top players in the field. Contact us!
Pharmaxon is a science-based biopharmaceutical company specializing in the discovery and development of innovative drugs controlling cell mobility. Our focus is on nervous system’s parthologies associated with cell mobility modifications and significant unmet medical needs. This novel scientific approach opens the way to efficient therapies for a range of poorly-treated diseases, lesions and cancers of the central and peripheral nervous systems.
Through the expertise of Prof. Camille Wermuth and the innovation of a young team of medicinal chemists led by Prof. Thierry Langer and Dr Bruno Giethlen, Prestwick Chemical prides itself to to fast forward our client’s projects to the clinics, i.e. to the market, reduce attrition and deliver excellent patentability. Our smart libraries enable quick and efficient screening with remarquable hit rates as composed essentially of marketed drugs. A selective optimization of side activities will then improved the hit compounds while maintaining the initial drug-likeness.
Prologue Biotech is a life science company incubator that currently hosts and supports 6 incorporated companies (Ambiotis, BT Pharma, PaluMed, Physiogenex, Urosphere, Vectalys), and 3 emerging projects (Dendris, Mycorrhize, Nanobiochips). Prologue Biotech has also favored the development of 2 evergrowing independent life-science companies (GTP Technology, MilleGen). In the heart of Toulouse-Labege-Innopole biopark, Prologue Biotech offers tailored facilities (1000 m² laboratories, 250 m² offices), services (animal facility, washing area, on-line scientific documentation, 4°C and 37°C stores, etc.), business development guidance and administrative support by an experienced team, and privileged access to available and upcoming biotech buildings.
Promogene builts for its clients « hand-made » molecular and cellular prototypes ( vectors, cell lines, systems of bioproduction, of regulation, of expression, …) in order to produce biological molecules aimed at exploration (scientific research area), at detection (molecular screening or identification of targets), and at treatment (gene vaccination, cellular and gene therapy). These prototypes are dedicated to the production of therapeutic molecules as well as the production of signaling molecules for objectives of research, detection and treatment.
Protéus is a leading biotechnology company dedicated to the discovery and design of novel proteins and protein-based processes and products for the life sciences and chemical industries. Proteus delivers unprecedented industrial performance by creating and improving bio-based products and processes. Since founding in 1998, Proteus provides tremendous opportunities for creating new functionality, addressing new needs and developing new markets. Opportunities also include improved second generation products and manufacturing processes.
TRANSAT is a research partner from gene to therapy. We propose customized services in: cellular engineering (cellular model design by RNAi & gene over expression, transfection optimization, viral vectors, immortalization…), RNAi libraries, functional assays and interferent screening, which is a new inescapable link in your process. Thanks to our innovative tools, TRANSAT allows you to manage risks in early drug development.
TxCell develop a new class of immunotherapy based on the administration of autologous regulatory cells (Tr1). These cells of the immune system and more specifically, adaptive immunity have large immunosuppressive properties. The start of the clinical trial in Crohn (Ph I/IIa) disease (In Lille with Pr Desreumaux) is an important step because it should validate the concept with the first therapeutic clinical results expected by the end of 2008. This proof of concept will accelerating further clinical trials based on the same technology platform in Rheumatoid Arthritis (CellArthrix) and two orphans indications the juvenile idiopathic arthritis and Wegener's disease.
